Novo Nordisk | NVO - Gross Profit On Sales


Novo Nordisk reported DKK64.01B in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
ANI Pharmaceuticals USD 111.79M 1.68M Sep/2025
Aurora Cannabis CAD 32.29M 4.34M Sep/2025
Bausch Health Companies USD 1.93B 165M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Canopy Growth CAD 21.9M 3.86M Sep/2025
Corcept Therapeutics USD 199.58M 3.46M Dec/2025
Drreddys Laboratories INR 46.81B 10.24B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Merck USD 13.42B 431M Sep/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Novartis USD 10.82B 695M Sep/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pacira USD 142.25M 11.34M Dec/2025
Perrigo USD 362.2M 14.9M Dec/2025
Phibro Animal Health USD 101.87M 18.38M Dec/2024
Prestige Brands USD 157.37M 5.79M Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
Zoetis USD 1.64B 73M Dec/2025